| |
Total n = 190
|
Saxagliptin n = 66
|
Vildagliptin n = 63
|
Sitagliptin n = 61
|
p value
|
|---|
|
Age (years), mean ± SD
|
46.6 ± 9.0
|
46.5 ± 10.7
|
44.8 ± 8.5
|
48.6 ± 11.3
|
0.90
|
|
Range
|
23 ~ 72
|
23 ~ 72
|
25 ~ 63
|
29 ~ 70
|
-
|
|
Age (years), n (%)
|
|
<50 years
|
53(28%)
|
18(27%)
|
18(29%)
|
17(27%)
|
0.99
|
|
50 ~ 65 years
|
90(47%)
|
31(47%)
|
29(46%)
|
30(50%)
|
0.94
|
|
>65 years
|
47(25%)
|
17(26%)
|
16(25%)
|
14(23%)
|
0.93
|
|
Gender, n (%)
|
|
Male
|
109(57%)
|
39(59%)
|
37(59%)
|
33(54%)
|
0.82
|
|
Female
|
81(43%)
|
27(41%)
|
26(41%)
|
28(46%)
|
0.82
|
|
Duration of diabetes (years), n (%)
|
|
<1 year
|
61(32%)
|
20(30%)
|
24(38%)
|
17(28%)
|
0.44
|
|
1 ~ 5 years
|
69(36%)
|
24(37%)
|
21(33%)
|
24(40%)
|
0.79
|
|
>5 years
|
60(32%)
|
22(33%)
|
18(29%)
|
20(32%)
|
0.82
|
|
Body weight (kg), mean ± SD
|
74.4 ± 11.1
|
77.2 ± 15.1
|
72.7 ± 11.3
|
73.2 ± 10.9
|
0.89
|
|
BMI (kg/m2), mean ± SD
|
26.3 ± 2.8
|
26.9 ± 3.1
|
25.3 ± 2.8
|
26.6 ± 3.3
|
0.80
|
|
HbA1c (%), mean ± SD
|
8.72 ± 1.01
|
8.86 ± 1.13
|
8.75 ± 1.15
|
8.54 ± 1.19
|
0.94
|
|
FBG (mmol/l), mean ± SD
|
8.46 ± 1.61
|
8.36 ± 2.04
|
8.79 ± 1.80
|
8.22 ± 1.77
|
0.93
|
|
P2hBG(mmol/l), mean ± SD
|
11.58 ± 2.49
|
11.77 ± 3.07
|
11.98 ± 2.46
|
10.98 ± 2.93
|
0.90
|
|
Therapy, n (%)
|
|
Metformin with glimepiride
|
77(41%)
|
26(40%)
|
26(41%)
|
25(41%)
|
0.97
|
|
Metformin with acarbose
|
62(33%)
|
22(33%)
|
20(32%)
|
20(33%)
|
0.98
|
|
Metformin with pioglitazone
|
51(26%)
|
18(27%)
|
17(27%)
|
16(26%)
|
0.99
|
- Abbreviations: BMI body mass index; FBG fasting blood glucose; P2hBG postprandial 2 hours’ blood glucose.
- Data are presented as mean ± standard deviation, as well as, n and%.
